PARADIGM BIO. ORDINARY (PAR) Short Interest
PARADIGM BIO. ORDINARY (ASX:PAR) had 0.00% of shares reported as short positions as of 26 June 2026, representing 5 shares. PARADIGM BIO. ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
PAR
Paradigm Biopharmaceuticals Limited..
Pharmaceuticals, Biotechnology & Life Sciences
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Shorted
short percentage0.00%
reported shorts5
shares on issue586.639M